NewLimit raised a $130M series B round last week to advance its work using epigenetic reprogramming to improve cell function and thus aim to extend longevity | BiotechTV - News | Podwise
NewLimit raised a $130M series B round last week to advance its work using epigenetic reprogramming to improve cell function and thus aim to extend longevity
BiotechTV - News - NewLimit raised a $130M series B round last week to advance its work using epigenetic reprogramming to improve cell function and thus aim to extend longevity
Sign in to continue reading, translating and more.
